目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 BIOLOGICS SAFETY TESTING MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED
1.3 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES: BIOLOGICS SAFETY TESTING MARKET
2.1.3 DATA TRIANGULATION APPROACH
2.2 DATA TRIANGULATION
FIGURE 4 DATA TRIANGULATION METHODOLOGY
2.3 MARKET ESTIMATION METHODOLOGY
FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL ANALYSIS-BASED ESTIMATION
FIGURE 7 BIOLOGICS SAFETY TESTING MARKET: FINAL CAGR PROJECTION (2022−2027)
FIGURE 8 BIOLOGICS SAFETY TESTING: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
2.6 RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024−2027 (% GROWTH)

3 EXECUTIVE SUMMARY (Page No. - 44)
FIGURE 9 BIOLOGICS SAFETY TESTING MARKET SHARE, BY PRODUCT & SERVICE (2021)
FIGURE 10 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES

4 PREMIUM INSIGHTS (Page No. - 48)
4.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW
FIGURE 13 RISING DEVELOPMENT OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
4.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION AND COUNTRY (2021)
FIGURE 14 MONOCLONAL ANTIBODIES MANUFACTURING SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE
FIGURE 15 RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 51)
5.1 MARKET DYNAMICS
FIGURE 16 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 DRIVERS
5.1.1.1 Growing development of biosimilars and biologics
TABLE 2 LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN US, 2021
TABLE 3 LIST OF BIOLOGICS APPROVED BY US FDA (2021)
5.1.1.2 Growing concerns over cell culture contamination
5.1.1.3 Rising investments in biopharmaceutical R&D
TABLE 4 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)
FIGURE 17 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2017-2024
5.1.2 RESTRAINTS
5.1.2.1 Shortage of skilled professionals
5.1.3 OPPORTUNITIES
5.1.3.1 Emerging markets
5.1.3.2 Increasing outsourcing of biopharmaceutical activities to CROs
5.1.4 CHALLENGES
5.1.4.1 High cost of biologics
5.2 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS (2020-2021)
5.2.1 PRICING TREND ANALYSIS
5.3 VALUE CHAIN ANALYSIS
FIGURE 18 BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
FIGURE 19 BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
FIGURE 20 REVENUE SHIFT FOR BIOLOGICS SAFETY TESTING PROVIDERS
5.6 PATENT ANALYSIS
FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR BIOLOGICS SAFETY PATENTS (JANUARY 2012−NOVEMBER 2022)
TABLE 6 BIOLOGICS SAFETY TESTING MARKET: INDICATIVE LIST OF PATENTS
5.7 REGULATORY ANALYSIS
5.7.1 US
5.7.2 EUROPE
5.7.3 ASIA PACIFIC
5.7.4 LATIN AMERICA
5.7.5 MIDDLE EAST AND AFRICA
5.7.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PORTER'S FIVE FORCES ANALYSIS
TABLE 11 BIOLOGICS SAFETY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 KEY CONFERENCES AND EVENTS IN 2022-2023
TABLE 12 BIOLOGICS SAFETY TESTING MARKET: CONFERENCES AND EVENTS
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCTS & SERVICES
FIGURE 23 BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING PRODUCTS & SERVICES

6 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE (Page No. - 70)
6.1 INTRODUCTION
TABLE 13 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
6.2 SERVICES
6.2.1 INCREASING OUTSOURCING OF SERVICES TO CROS TO DRIVE MARKET
TABLE 14 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 15 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 16 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 17 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
6.3 CONSUMABLES
6.3.1 RECURRENT PURCHASE OF ASSAYS, KITS, AND REAGENTS TO DRIVE MARKET
TABLE 18 BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 19 NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 21 ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
6.4 INSTRUMENTS
6.4.1 LONGER SHELF LIFE OF INSTRUMENTS TO RESTRAIN MARKET
TABLE 22 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 23 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 24 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 25 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE (Page No. - 78)
7.1 INTRODUCTION
TABLE 26 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
7.2 RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS
7.2.1 GROWING USE OF RDNA IN VARIOUS MANUFACTURING STAGES TO DRIVE MARKET
TABLE 27 RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 28 NORTH AMERICA: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 29 EUROPE: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 30 ASIA PACIFIC: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.3 MYCOPLASMA TESTS
7.3.1 GROWING CONCERNS OVER CELL CULTURE CONTAMINATION TO DRIVE MARKET
TABLE 31 MYCOPLASMA TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 32 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 33 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 34 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.4 STERILITY TESTS
7.4.1 MANDATORY TESTING CONDUCTED FOR DRUG DEVELOPMENT & PRODUCTION TO DRIVE MARKET
TABLE 35 STERILITY TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 36 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 37 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 38 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.5 ENDOTOXIN TESTS
7.5.1 RISING DEMAND FOR LAL TESTING TO SUPPORT MARKET GROWTH
TABLE 39 ENDOTOXIN TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 40 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 41 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.6 VIRUS SAFETY TESTS
7.6.1 RISING UPTAKE IN VACCINE DEVELOPMENT AND CELL & GENE THERAPY TO SUPPORT MARKET
TABLE 43 VIRUS SAFETY TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 44 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 45 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 46 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.7 BIOBURDEN TESTS
7.7.1 GROWING CONCERNS FOR DRUG SAFETY STANDARDS TO PROPEL MARKET
TABLE 47 BIOBURDEN TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 48 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 49 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 50 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.8 OTHER BIOLOGICS SAFETY TESTS
TABLE 51 OTHER BIOLOGICS SAFETY TESTS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 52 NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 53 EUROPE: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 54 ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION (Page No. - 93)
8.1 INTRODUCTION
TABLE 55 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
8.2 MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING
8.2.1 RISING APPROVALS FOR BIOSIMILAR MABS TO DRIVE MARKET
TABLE 56 BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2020-2027 (USD MILLION)
TABLE 57 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 58 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 59 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
8.3 VACCINE DEVELOPMENT AND MANUFACTURING
8.3.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 60 BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY REGION, 2020-2027 (USD MILLION)
TABLE 61 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 62 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
8.4 CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING
8.4.1 RISING ADOPTION OF CELLULAR IMMUNOTHERAPIES FOR CANCER TREATMENT TO DRIVE MARKET
TABLE 64 BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING, BY REGION, 2020-2027 (USD MILLION)
TABLE 65 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 66 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 67 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
8.5 BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING
8.5.1 RISING UPTAKE OF STERILITY TESTS TO SUPPORT MARKET GROWTH
TABLE 68 BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY REGION, 2020-2027 (USD MILLION)
TABLE 69 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 70 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 71 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020-2027 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 72 BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
TABLE 73 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 74 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 75 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 BIOLOGICS SAFETY TESTING MARKET, BY END USER (Page No. - 105)
9.1 INTRODUCTION
TABLE 76 BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 GROWING R&D EXPENDITURE FOR DRUG DEVELOPMENT TO DRIVE MARKET
FIGURE 24 PHARMACEUTICAL R&D SPENDING (2014-2028)
TABLE 77 BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION)
TABLE 78 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 79 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS AND CDMOS)
9.3.1 ABILITY TO PROVIDE SPECIALIZED MANUFACTURING AND SAFETY TESTING TECHNOLOGIES TO DRIVE MARKET
TABLE 81 BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY REGION, 2020-2027 (USD MILLION)
TABLE 82 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CRS AND CDMOS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 83 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 84 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY COUNTRY, 2020-2027 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 AVAILABILITY OF ADVANCED EQUIPMENT AND SPECIALIZED R&D PERSONNEL TO SUPPORT MARKET GROWTH
TABLE 85 BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
TABLE 86 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 87 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 88 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)

10 BIOLOGICS SAFETY TESTING MARKET, BY REGION (Page No. - 113)
10.1 INTRODUCTION
TABLE 89 BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 25 BIOLOGICS SAFETY TESTING MARKET: NORTH AMERICA MARKET SNAPSHOT
TABLE 90 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 91 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 92 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 93 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 94 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.2.1 US
10.2.1.1 High investments in biopharmaceutical R&D to drive market
TABLE 95 US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 96 US: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 97 US: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 98 US: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Presence of R&D clusters and growing life sciences research to drive market
TABLE 99 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 100 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 101 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 102 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 103 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 104 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 105 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 106 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 107 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Favorable R&D funding by federal and state governments to propel market
TABLE 108 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 109 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 110 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 111 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing focus on investments in vaccine manufacturing to drive market
TABLE 112 UK: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 113 UK: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 114 UK: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 115 UK: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Government initiatives to strengthen R&D activities to support market growth
TABLE 116 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 117 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 118 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 119 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Favorable government support for establishment of biotech startups to propel market
TABLE 120 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 121 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 122 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 123 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing biologics production and outsourcing testing services to support market growth
TABLE 124 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 125 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 126 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 127 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 128 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 129 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 130 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 131 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
FIGURE 26 BIOLOGICS SAFETY TESTING MARKET: ASIA PACIFIC MARKET SNAPSHOT
TABLE 132 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 133 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 134 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 135 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 136 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USERS, 2020-2027 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Rising approvals for drug applications and high R&D innovation to drive market
TABLE 137 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 138 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 139 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 140 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Rising investments for establishment of cell & gene therapy facilities to propel market
TABLE 141 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 142 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 143 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 144 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 High demand for export of pharmaceuticals and vaccines to drive market
TABLE 145 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 146 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 147 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 148 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 149 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 150 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 151 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 152 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 LATIN AMERICA
10.5.1 GROWING APPROVAL OF BIOSIMILARS TO SUPPORT MARKET GROWTH
TABLE 153 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 154 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 155 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 156 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.5.2 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 RISING FOCUS ON DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 157 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
TABLE 159 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE (Page No. - 161)
11.1 OVERVIEW
11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 27 BIOLOGICS SAFETY TESTING MARKET: KEY PLAYER STRATEGIES (2019-2022)
11.3 MARKET SHARE ANALYSIS
FIGURE 28 BIOLOGICS SAFETY TESTING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2021 (TOP EIGHT)
TABLE 161 BIOLOGICS SAFETY TESTING MARKET: INTENSITY OF COMPETITIVE RIVALRY
11.4 REVENUE SHARE ANALYSIS OF KEY PLAYERS
FIGURE 29 BIOLOGICS SAFETY TESTING MARKET: REVENUE SHARE ANALYSIS OF KEY PLAYERS (TOP EIGHT)
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 30 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX, 2021
11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 DYNAMIC COMPANIES
11.6.4 RESPONSIVE COMPANIES
FIGURE 31 BIOLOGICS SAFETY TESTING: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS (2021)
11.7 COMPETITIVE BENCHMARKING
11.7.1 COMPANY PRODUCT FOOTPRINT
TABLE 162 BIOLOGICS SAFETY TESTING MARKET: PRODUCT PORTFOLIO ANALYSIS
11.7.2 COMPANY TEST TYPE FOOTPRINT
TABLE 163 BIOLOGICS SAFETY TESTING MARKET: TEST TYPE ANALYSIS
11.7.3 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 164 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC ANALYSIS
11.7.4 OVERALL COMPANY FOOTPRINT (25 COMPANIES)
TABLE 165 BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT
11.7.4.1 COMPETITIVE BENCHMARKING FOR STARTUPS
TABLE 166 BIOLOGICS SAFETY TESTING MARKET: KEY STARTUPS
TABLE 167 BIOLOGICS SAFETY TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS
11.8 COMPETITIVE SCENARIO
11.8.1 BIOLOGICS SAFETY TESTING MARKET: PRODUCT LAUNCHES (JANUARY 2019−DECEMBER 2022)
11.8.2 BIOLOGICS SAFETY TESTING MARKET: DEALS (JANUARY 2019−DECEMBER 2022)
11.8.3 BIOLOGICS SAFETY TESTING MARKET: OTHER DEVELOPMENTS (JANUARY 2019−DECEMBER 2022)

12 COMPANY PROFILES (Page No. - 178)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 CHARLES RIVER LABORATORIES
TABLE 168 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.2 LONZA
TABLE 169 LONZA: BUSINESS OVERVIEW
FIGURE 33 LONZA: COMPANY SNAPSHOT (2021)
12.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 170 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
12.1.4 MERCK KGAA
TABLE 171 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2021)
12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
FIGURE 36 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
12.1.6 SGS SA
TABLE 173 SGS SA: BUSINESS OVERVIEW
FIGURE 37 SGS SA: COMPANY SNAPSHOT (2021)
12.1.7 EUROFINS SCIENTIFIC
TABLE 174 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
12.1.8 WUXI APPTEC
TABLE 175 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 39 WUXI APPTEC: COMPANY SNAPSHOT (2021)
12.1.9 ASSOCIATES OF CAPE COD, INC.
TABLE 176 ASSOCIATES OF CAPE COD, INC.: BUSINESS OVERVIEW
12.1.10 BIOMÉRIEUX SA
TABLE 177 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 40 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
12.1.11 SAMSUNG BIOLOGICS
TABLE 178 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
FIGURE 41 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2021)
12.1.12 GENSCRIPT
TABLE 179 GENSCRIPT: BUSINESS OVERVIEW
FIGURE 42 GENSCRIPT: COMPANY SNAPSHOT (2021)
12.1.13 SARTORIUS AG
TABLE 180 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 43 SARTORIUS AG: COMPANY SNAPSHOT (2021)
12.1.14 F. HOFFMANN-LA ROCHE LTD.
TABLE 181 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
12.1.15 PACIFIC BIOLABS
TABLE 182 PACIFIC BIOLABS: BUSINESS OVERVIEW
12.1.16 NELSON LABORATORIES, LLC (PART OF SOTERA HEALTH)
TABLE 183 NELSON LABORATORIES: BUSINESS OVERVIEW
12.1.17 AGILENT TECHNOLOGIES, INC.
TABLE 184 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 45 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
12.1.18 MARAVAI LIFESCIENCES
TABLE 185 MARAVAI LIFESCIENCES: BUSINESS OVERVIEW
FIGURE 46 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2021)
12.2 OTHER PLAYERS
12.2.1 QIAGEN
12.2.2 BIO-RAD LABORATORIES, INC.
12.2.3 MICROCOAT BIOTECHNOLOGIE GMBH
12.2.4 INVIVOGEN
12.2.5 PROMOCELL GMBH
12.2.6 ACCUGEN LABORATORIES, INC.
12.2.7 FUJIFILM WAKO PURE CHEMICAL CORPORATION
12.2.8 ALMAC GROUP
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 244)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS